Brian D Kavanagh

List of Publications by Year
in descending order

129	11,156	57758 44	30087 103
papers	citations	h-index	g-index

129	129	129	9174
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib. Clinical Lung Cancer, 2022, 23, e5-e8.	2.6	11
2	Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry. Journal of Neurosurgery, 2022, 137, 985-998.	1.6	4
3	Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. Clinical Genitourinary Cancer, 2021, 19, 217-222.e1.	1.9	7
4	High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1-10.	0.8	60
5	The HyTEC Project. Medical Physics, 2021, 48, 2699-2700.	3.0	1
6	No Longer a Match: Trends in Radiation Oncology National Resident Matching Program (NRMP) Data from 2010-2020 and Comparison Across Specialties. International Journal of Radiation Oncology Biology Physics, 2021, 110, 278-287.	0.8	29
7	The Economics of Using Locally Ablative Therapy in Oligometastatic Cancer. Seminars in Radiation Oncology, 2021, 31, 250-252.	2.2	1
8	Navigating Past the Chaos of the Radiation Oncology 2021 Match. International Journal of Radiation Oncology Biology Physics, 2021, 111, 328-330.	0.8	1
9	The Virtual Visiting Professor: A Step Toward a Parasocial Common Curriculum?. International Journal of Radiation Oncology Biology Physics, 2020, 108, 466-469.	0.8	1
10	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology, 2020, 6, 1028.	7.1	122
11	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.8	40
12	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.6	168
13	Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, 346-355.	0.8	115
14	Halfway Toward Half Full. International Journal of Radiation Oncology Biology Physics, 2019, 104, 997-998.	0.8	1
15	Model Insurance Coverage Policies: The Power of Suggestion, the Force of Evidence. International Journal of Radiation Oncology Biology Physics, 2019, 104, 745-747.	0.8	1
16	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Nonâ€“Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 2019, 37, 1558-1565.	1.6	882
17	Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clinical Cancer Research, 2019, 25, 3946-3953.	7.0	46
18	Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer. Lung Cancer, 2018, 120, 88-90.	2.0	47

#	Article	IF	Citations
19	Medical operability and inoperability drive survival in retrospective analyses comparing surgery and SBRT for early-stage lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 810-811.	0.8	8
20	Excellent Outcomes with Radiosurgery for MultipleÂBrain Metastases in ALK and EGFR DrivenÂNonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 715-720.	1.1	48
21	Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 642-651.	1.6	111
22	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. Journal of Neuro-Oncology, 2018, 140, 55-62.	2.9	25
23	Honor Was Never Lost: The National Farm Machinery Show and the American Society for Radiation Oncology Annual Meeting. International Journal of Radiation Oncology Biology Physics, 2018, 101, 259-260.	0.8	0
24	Management of Brain Metastases in Tyrosine Kinase Inhibitorâ€“NaÃ¯ve Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 2017, 35, 1070-1077.	1.6	372
25	The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Nonâ€“Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2017, 35, 1749-1751.	1.6	11
26	The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. Journal of Thoracic Oncology, 2017, 12, 734-744.	1.1	94
27	Stereotactic Body Radiotherapy for Liver Metastases. Seminars in Radiation Oncology, 2017, 27, 240-246.	2.2	25
28	Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise. Journal of Thoracic Oncology, 2017, 12, 1746-1754.	1.1	48
29	National trends in radiotherapy for brain metastases at time of diagnosis of non-small cell lung cancer. Journal of Clinical Neuroscience, 2017, 45, 48-53.	1.5	32
30	Prophylactic cranial irradiation in small-cell lung cancer. Lancet Oncology, The, 2017, 18, e365.	10.7	5
31	Survival benefit of postoperative radiation in papillary meningioma: Analysis of the National Cancer Data Base. Reports of Practical Oncology and Radiotherapy, 2017, 22, 495-501.	0.6	13
32	Reply to J.B. Aragon-Ching and D. Dalela et al. Journal of Clinical Oncology, 2017, 35, 916-917.	1.6	0
33	Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1357-1366.	0.8	134
34	Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era. JAMA Neurology, 2016, 73, 821.	9.0	46
35	Stereotactic body radiation therapy for low and intermediate risk prostate cancerâ€”Results from a multi-institutional clinical trial. European Journal of Cancer, 2016, 59, 142-151.	2.8	124
36	Stereotactic Body Irradiation. , 2016, , 427-431.e1.		1

#	Article	IF	Citations
37	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncology, The, 2016, 17, 1672-1682.	10.7	865
38	From the Guest Editor. Cancer Journal (Sudbury, Mass), 2016, 22, 245-246.	2.0	0
39	Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2835-2842.	1.6	213
40	Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM). Journal of Radiation Oncology, 2016, 5, 33-39.	0.7	2
41	How Will Big Data Impact Clinical Decision Making and Precision Medicine in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 880-884.	0.8	22
42	Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. Journal of Urology, 2016, 195, 1453-1458.	0.4	22
43	Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy, 2016, 15, 136-146.	0.5	8
44	Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 165.e1-165.e9.	1.6	12
45	Inception of a national multidisciplinary registry for stereotactic radiosurgery. Journal of Neurosurgery, 2016, 124, 155-162.	1.6	37
46	Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Nonâ€“Small-Cell Lung Cancer and Brain Metastasis. Journal of Clinical Oncology, 2016, 34, 123-129.	1.6	284
47	Stereotactic Irradiation. , 2016, , 419-426.e2.		1
48	Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer. Annals of Translational Medicine, 2016, 4, 14.	1.7	1
49	Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiation Oncology, 2015, 10, 218.	2.7	48
50	Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2015, 122, 135-143.	2.9	29
51	In Regard to Jagsi etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 91, 679-680.	0.8	1
52	Clinical Validation of 4-Dimensional Computed Tomography Ventilation With Pulmonary Function Test Data. International Journal of Radiation Oncology Biology Physics, 2015, 92, 423-429.	0.8	59
53	Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?. Practical Radiation Oncology, 2015, 5, e589-e596.	2.1	59
54	Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 71.e11-71.e19.	1.6	27

#	Article	IF	Citations
55	Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Journal of Neuro-Oncology, 2015, 123, 251-257.	2.9	22
56	Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1052-1063.	0.8	32
57	External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1987-1988.	1.6	12
58	Radiation Oncologist Concerns About Increased Electronic Brachytherapy Use for Skin Cancer. JAMA Dermatology, 2015, 151, 1036.	4.1	7
59	Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. Annals of Translational Medicine, 2015, 3, 149.	1.7	8
60	Radiation Oncology: A Snapshot in Time, 2014. Journal of Clinical Oncology, 2014, 32, 2825-2826.	1.6	6
61	Hypofractionated intensityâ€modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 714-721.	1.8	11
62	Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate- and high-risk prostate cancer. Journal of Radiation Oncology, 2014, 3, 401-407.	0.7	0
63	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 3824-3830.	1.6	244
64	Stereotactic Body Radiation Therapy As a Derivative of Stereotactic Radiosurgery: Clinically Independent But With Enduring Common Themes. Journal of Clinical Oncology, 2014, 32, 2827-2831.	1.6	8
65	Radiation Oncology: A Perspective on Health Reform and Value-Based Initiatives. Journal of Oncology Practice, 2014, 10, e212-e214.	2.5	4
66	Comparison of 4-Dimensional Computed Tomography Ventilation With Nuclear Medicine Ventilation-Perfusion Imaging: A Clinical Validation Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 199-205.	0.8	50
67	Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. International Journal of Radiation Oncology Biology Physics, 2014, 88, 892-898.	0.8	182
68	The Impact of Definitive Local Therapy for Lymph Node-Positive Prostate Cancer: A Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1064-1073.	0.8	94
69	Stereotactic body radiation therapy (SBRT) for liver metastases: A clinical review. Seminars in Colon and Rectal Surgery, 2014, 25, 48-52.	0.3	8
70	The Impact of Adjuvant Radiation Therapy for High-Grade Gliomas by Histology in the United States Population. International Journal of Radiation Oncology Biology Physics, 2014, 90, 894-902.	0.8	23
71	Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 509-517.	0.8	177
72	Comparison of Radiation-Induced Normal Lung Tissue Density Changes for Patients From Multiple Institutions Receiving Conventional or Hypofractionated Treatments. International Journal of Radiation Oncology Biology Physics, 2014, 89, 626-632.	0.8	16

#	Article	IF	Citations
73	The prognostic significance of Gleason scores in metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 707-713.	1.6	48
74	Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. Journal of Neuro-Oncology, 2013, 114, 111-116.	2.9	30
75	Improved Cosmesis in Early Breast Cancer Using Conformal Radiotherapy. Journal of Clinical Oncology, 2013, 31, 4483-4484.	1.6	6
76	Physicists who are responsible for highâ€tech radiotherapy procedures should have to be specially credentialed. Medical Physics, 2012, 39, 7181-7184.	3.0	0
77	Highâ€dose MVCT image guidance for stereotactic body radiation therapy. Medical Physics, 2012, 39, 4812-4819.	3.0	14
78	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1807-1814.	1.1	585
79	Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2012, 84, 655-660.	0.8	72
80	Fluorodeoxyglucose Positron Emission Tomography Response and Normal Tissue Regeneration After Stereotactic Body Radiotherapy to Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 83, e613-e618.	0.8	29
81	Normal Liver Tissue Density Dose Response in Patients Treated With Stereotactic Body Radiation Therapy for Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 84, e441-e446.	0.8	21
82	Presumed early-stage lung cancer treated with stereotactic body radiation therapy in a medically inoperable patient with multiple connective tissue disorders. Practical Radiation Oncology, 2012, 2, e133-e136.	2.1	1
83	Stereotactic ablative radiotherapy: what's in a name?. Practical Radiation Oncology, 2011, 1, 38-39.	2.1	53
84	The Expanding Roles of Stereotactic Body Radiation Therapy and Oligofractionation: Toward a New Practice of Radiotherapy. Frontiers of Radiation Therapy and Oncology, 2011, 43, 370-381.	1.4	13
85	Phase I Trial of Hypofractionated Intensity-Modulated Radiotherapy With Temozolomide Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1066-1074.	0.8	46
86	Advances in Treatment Techniques. Cancer Journal (Sudbury, Mass), 2011, 17, 177-181.	2.0	27
87	Hepatic Radiation Toxicity: Avoidance and Amelioration. Seminars in Radiation Oncology, 2011, 21, 256-263.	2.2	176
88	Radiation Therapy for Liver Metastases. Seminars in Radiation Oncology, 2011, 21, 264-270.	2.2	40
89	Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiation Oncology, 2011, 6, 34.	2.7	137
90	Stereotactic body radiotherapy for colorectal liver metastases. Cancer, 2011, 117, 4060-4069.	4.1	265

#	Article	IF	Citations
91	Favorable Prognosis in Patients With High-Grade Glioma With Radiation Necrosis: The University of Colorado Reoperation Series. International Journal of Radiation Oncology Biology Physics, 2011, 81, 211-217.	0.8	37
92	Tracing the earliest medical uses of high dose-per-fraction external beam radiation. Journal of Radiosurgery and SBRT, 2011, 1, 5-11.	0.2	2
93	Back to the future: a proton pro/con. Oncology, 2011, 25, 657, 660, 662-3.	0.5	0
94	Chest Wall Volume Receiving >30 Gy Predicts Risk of Severe Pain and/or Rib Fracture After Lung Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 796-801.	0.8	261
95	Radiation-Associated Liver Injury. International Journal of Radiation Oncology Biology Physics, 2010, 76, S94-S100.	0.8	592
96	Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases. Journal of Clinical Oncology, 2009, 27, 1579-1584.	1.6	729
97	Reply to X. Mirabel. Journal of Clinical Oncology, 2009, 27, e41-e41.	1.6	3
98	Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. Journal of Clinical Oncology, 2009, 27, 1572-1578.	1.6	753
99	Radiographic and Histopathologic Observations After Combined EGFR Inhibition and Hypofractionated Stereotactic Radiosurgery in Patients With Recurrent Malignant Gliomas. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1352-1357.	0.8	16
100	Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta OncolÃ³gica, 2009, 48, 578-583.	1.8	153
101	A Phase I Dose-Escalation Study of Fractionated Stereotactic Radiosurgery in Combination With Gefitinib in Patients With Recurrent Malignant Gliomas. International Journal of Radiation Oncology Biology Physics, 2008, 70, 993-1001.	0.8	65
102	Stereotactic Body Radiation Therapy: A New Paradigm in Radiotherapy Management of Cancer. Journal of the American College of Radiology, 2008, 5, 673-677.	1.8	3
103	Liver, Renal, and Retroperitoneal Tumors: Stereotactic Radiotherapy. , 2007, 40, 415-426.		14
104	The North American Experience with Stereotactic Body Radiation Therapy in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S101-S112.	1.1	124
105	Stereotactic Body Radiation Therapy in Multiple Organ Sites. Journal of Clinical Oncology, 2007, 25, 947-952.	1.6	401
106	Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: An Overview of Technical Considerations and Clinical Applications. Hematology/Oncology Clinics of North America, 2006, 20, 87-95.	2.2	27
107	Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta OncolÃ³gica, 2006, 45, 848-855.	1.8	188
108	The dosimetric effect of inhomogeneity correction in dynamic conformal arc stereotactic body radiation therapy for lung tumors. Journal of Applied Clinical Medical Physics, 2006, 7, 58-63.	1.9	14

#	Article	IF	Citations
109	A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. International Journal of Radiation Oncology Biology Physics, 2006, 66, S120-S127.	0.8	26
110	Extracranial Radiosurgery (Stereotactic Body Radiation Therapy) for Oligometastases. Seminars in Radiation Oncology, 2006, 16, 77-84.	2.2	125
111	A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1371-1378.	0.8	384
112	Stereotactic Body Radiation Therapy. Current Problems in Cancer, 2005, 29, 120-157.	2.0	63
113	The emperor's new isodose curves. Medical Physics, 2003, 30, 2559-2560.	3.0	3
114	Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Seminars in Radiation Oncology, 2002, 12, 260-271.	2.2	60
115	Technical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer. Medical Dosimetry, 2002, 27, 177-184.	0.9	25
116	A theoretical model for the effects of reduced hemoglobin-oxygen affinity on tumor oxygenation. International Journal of Radiation Oncology Biology Physics, 2002, 53, 172-179.	0.8	28
117	Long-term Local Control and Survival After Concomitant Boost Accelerated Radiotherapy for Locally Advanced Cervix Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 113-119.	1.3	9
118	Gynecologic Brachytherapy: Digital Fluoroscopy for Placement Verification and Treatment Planning. Radiology, 2000, 215, 900-903.	7.3	3
119	Recurrent Cervical Carcinoma: Typical and Atypical Manifestations. Radiographics, 1999, 19, S103-S116.	3.3	84
120	Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. International Journal of Radiation Oncology Biology Physics, 1999, 45, 515-520.	0.8	43
121	Calcium-Dependent Stimulation of Mitogen-Activated Protein Kinase Activity in A431 Cells by Low Doses of Ionizing Radiation. Radiation Research, 1998, 149, 579.	1.5	63
122	A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 1997, 38, 561-568.	0.8	26
123	Clinical use of a digital simulator for rapid setup verification in high dose rate brachytherapy. International Journal of Radiation Oncology Biology Physics, 1995, 33, 931-936.	0.8	2
124	In response to Deore et al.. International Journal of Radiation Oncology Biology Physics, 1995, 32, 556.	0.8	1
125	Soft tissue complication rates after low dose rate brachytherapy using customized perineal templates. International Journal of Radiation Oncology Biology Physics, 1994, 30, 508.	0.8	9
126	Radiation Therapy for Head and Neck Cancer in a Patient with Takayasu's Arteritis. Acta OncolÃ³gica, 1994, 33, 73-74.	1.8	1

#	Article	IF	Citations
127	Syndrome of inappropriate secretion of antidiuretic hormone in a patient with carcinoma of the nasopharynx. Cancer, 1993, 72, 299-299.	4.1	0
128	Long-term results of combined modality therapy for esophageal cancer. Radiation Oncology Investigations, 1993, 1, 227-234.	0.9	2
129	Syndrome of inappropriate secretion of antidiuretic hormone in a patient with carcinoma of the nasopharynx. Cancer, 1992, 69, 1315-1319.	4.1	26